1. Home
  2. LQDT vs AKBA Comparison

LQDT vs AKBA Comparison

Compare LQDT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDT
  • AKBA
  • Stock Information
  • Founded
  • LQDT 1999
  • AKBA 2007
  • Country
  • LQDT United States
  • AKBA United States
  • Employees
  • LQDT N/A
  • AKBA N/A
  • Industry
  • LQDT Catalog/Specialty Distribution
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • LQDT Consumer Discretionary
  • AKBA Health Care
  • Exchange
  • LQDT Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • LQDT 859.6M
  • AKBA 861.7M
  • IPO Year
  • LQDT 2006
  • AKBA 2014
  • Fundamental
  • Price
  • LQDT $23.26
  • AKBA $2.79
  • Analyst Decision
  • LQDT Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • LQDT 2
  • AKBA 5
  • Target Price
  • LQDT $38.50
  • AKBA $6.90
  • AVG Volume (30 Days)
  • LQDT 186.4K
  • AKBA 2.9M
  • Earning Date
  • LQDT 08-07-2025
  • AKBA 11-06-2025
  • Dividend Yield
  • LQDT N/A
  • AKBA N/A
  • EPS Growth
  • LQDT 33.77
  • AKBA N/A
  • EPS
  • LQDT 0.83
  • AKBA N/A
  • Revenue
  • LQDT $465,508,000.00
  • AKBA $203,733,000.00
  • Revenue This Year
  • LQDT $31.57
  • AKBA $43.91
  • Revenue Next Year
  • LQDT $2.58
  • AKBA $32.09
  • P/E Ratio
  • LQDT $27.94
  • AKBA N/A
  • Revenue Growth
  • LQDT 38.40
  • AKBA 16.75
  • 52 Week Low
  • LQDT $21.23
  • AKBA $1.26
  • 52 Week High
  • LQDT $39.72
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • LQDT 26.35
  • AKBA 44.92
  • Support Level
  • LQDT $26.92
  • AKBA $2.83
  • Resistance Level
  • LQDT $27.88
  • AKBA $3.02
  • Average True Range (ATR)
  • LQDT 0.75
  • AKBA 0.12
  • MACD
  • LQDT -0.56
  • AKBA 0.03
  • Stochastic Oscillator
  • LQDT 1.92
  • AKBA 40.28

About LQDT Liquidity Services Inc.

Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: